How many clinical-trial readouts are scheduled for May 2027?

pdufa.bio currently tracks 26 clinical-trial readouts with dates in May 2027, each linked to a primary source. The list updates as new filings appear and dates shift.

What is a clinical-trial readout date?

A readout date is the estimated time a trial reports topline results, based on its registered primary-completion date; these are estimates and shift.

Does pdufa.bio predict whether these will be approved?

No. We do not publish per-drug approval probabilities. We provide the verified facts, primary-source links, and historical base rates so you can judge for yourself.

pdufa.bio

Calendar Readouts Devices Decisions Approvals/yr Trial odds Learn Research Methodology

Home › Readouts › May 2027

May 2027 clinical-trial readouts

trial-readout estimates for May 2027, each row linked to its primary source. Readout dates are estimated primary-completion windows from ClinicalTrials.gov and shift.

← April 2027 June 2027 →

26 readouts

TELO · May 2027 (est.)

Zn-Telomir — Triple-Negative Breast Cancer (TNBC)

TNGX · May 2027 (est.)

S095035 — MTAP-deleted Solid Tumors

VOR · May 2027 (est.)

Telitacicept — Generalized Myasthenia Gravis

VYGR · May 2027 (est.)

VY7523 — Alzheimer's Disease (AD)

XENE · May 2027 (est.)

Azetukalner — Major Depressive Disorder

ZURA · May 2027 (est.)

Tibulizumab — Systemic Sclerosis (SSc)

SPTX · May 2027 (est.)

SPT-300 — Major Depressive Disorder (MDD)

IOVA · May 2027 (est.)

Lifileucel plus Pembrolizumab — Uveal Melanoma

IMVT · May 2027 (est.)

IMVT-1402 — Graves' Disease

BOLT · May 2027 (est.)

BDC-4182 — Gastric Cancer Adenocarcinoma Metastatic

CMPX · May 2027 (est.)

CTX-009 — Metastatic Biliary Tract Cancer

CRNX · May 2027 (est.)

Atumelnant — Congenital Adrenal Hyperplasia

GH · May 2027 (est.)

FOLFIRI+cetuximab — Metastatic Non-small Cell Lung Cancer

SLDB · May 2027 (est.)

SGT-003 — Duchenne Muscular Dystrophy

REGN · May 2027 (est.)

Cemiplimab — Recurrent Ovarian Cancer

REGN · May 2027 (est.)

Cemiplimab — Non-Small Cell Lung Cancer

FDMT · May 2027 (est.)

4D-150 IVT — Choroideremia

MBX · May 2027 (est.)

MBX 2109 — Hypoparathyroidism

ALNY · May 2027 (est.)

ALN-4324 — Type 2 Diabetes Mellitus (T2DM)

OLMA · May 2027 (est.)

Palazestrant — Advanced or Metastatic ER+ HER2- Breast Cancer (mBC)

ZLAB · May 2027 (est.)

ZL-1310 — SCLC

ACRV · May 2027 (est.)

ACR-368 — Endometrial Adenocarcinoma

BIIB · May 2027 (est.)

Felzartamab — Immunoglobulin A Nephropathy (IgAN)

GERN · May 2027 (est.)

Imetelstat — Phase II

RIGL · May 2027 (est.)

Fostamatinib Disodium — Acute Respiratory Distress Syndrome

RVMD · May 2027 (est.)

RMC-6236 — Non-small Cell Lung Cancer (NSCLC)

Looking for an approval probability for these? We deliberately don't publish one — here's why, and what we show instead (verified history + base rates).